CMND

CMND

Clearmind Medicine Inc.

6.40 USD

Last updated Oct 7, 18:09 UTC

Yesterday HIGH

$6.17

Yesterday LOW

$5.7

52w HIGH

$384

52w LOW

$1.76

EPS

-5.60

PE

-1.14

Next Earnings

Jan 19, 2027

Overview News Government Trades Fundamentals

Clearmind Medicine Inc. stock is down -22.33% since 30 days ago. The next earnings date is Jan 19, 2027. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 October’s closed higher than September.

Benzinga Newsdesk

Thu Jul 30, 2026

Clearmind Medicine Announces Safety Results From Part A Of Its Ongoing FDA-regulated Phase I/II Clinical Trial Evaluating CMND-100; All 24 Participants Enrolled Across Four Ascending-Dose Cohorts Successfully Completed Treatment

Completed treatment as planned per-protocol, reinforcing the strength of its proprietary drug candidate, CMND-100. The study achieved its primary endpoint of safety and tolerability. CMND-100 demonstrated a consistent
Benzinga Newsdesk

Tue Jul 28, 2026

Clearmind Medicine Completes Treatment For All Participants In Part A Of Its Ongoing Phase I/II Clinical Trial Evaluating CMND-100 For Alcohol Use Disorder

All 24 participants across cohorts 1 through 4 have successfully completed treatment according to the study protocol.The Company is currently assessing the dataset and, assuming results remain favorable, intends to
Benzinga Newsdesk

Mon Jul 20, 2026

Clearmind Medicine Files Hong Kong Patent Application For Innovative Psychedelic Compounds For Treatment Of Post-Traumatic Stress Disorder

The Hong Kong patent application forms part of Clearmind’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem ("Yissum"). Under the terms of
Benzinga Newsdesk

Thu Jul 16, 2026

Clearmind Medicine Announces Ex Vivo Mucoadhesion Results For Intranasal MEAI; New Formulation Demonstrated Markedly Improved Nasal Residence Characteristics Compared With Standard MEAI Solution

Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind’s strategy of developing differentiated, next‑generation treatments for AUD and
Benzinga Newsdesk

Mon Jul 13, 2026

CMND stock has given up its prior gain. Clearmind Medicine shares were trading higher after the company announced an update based on their "hands-on" experience from the CMND-100 trial.
Benzinga Newsdesk

Mon Jul 13, 2026

CORRECTION: Clearmind Medicine shares are trading lower.
Benzinga Newsdesk

Mon Jul 13, 2026

Clearmind Medicine Announces CMND‑100, Current Phase I/IIa Trial Demonstrates Impression To Treat Alcohol Use Disorder

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,
Benzinga Newsdesk

Fri Jul 10, 2026

Clearmind Medicine Files Response To U.S. Department Of Health And Human Services Request For Information About MEAI's Potential To Treat Addiction

Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage a biotech company developing novel, non-hallucinogenic, next-generation, neuroplastogen-derived therapeutics to solve major under-treated mental health problems,
Benzinga Newsdesk

Tue Jul 7, 2026

Clearmind Medicine Announces Progress In Evaluating Intranasal Delivery Of Its Proprietary MEAI Treatment For Alcohol Use Disorder

The program is evaluating intranasal delivery of MEAI as a potential additional route of administration, with initial studies focused on assessing formulation feasibility and supporting the continued development of this
Benzinga Newsdesk

Mon Jun 29, 2026

Clearmind Medicine Granted Additional US Patent Titled BINGE BEHAVIOR REGULATORS By USPTO

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,

SPCX $165.80 USD

ADUR $11.10 USD

WYNN $74.86 USD

APLD $23.93 USD

SMCI $44.63 USD

VOYG $28.13 USD

SKHY SKHY $178.88 USD

IREN $38.54 USD